The Wegovy injectable pen: what it actually does (and what it doesn't)

The myth: the injectable pen is complicated to use

A surprisingly large number of people delay starting Wegovy because they picture something clinical and fiddly, a syringe drawn from a vial, a needle they need to attach themselves, a dose they have to calculate. That picture is wrong, and it is worth saying so plainly before anything else.

The Wegovy pen is a pre-filled, single-use auto-injector. The needle is hidden inside the device. You press the pen against your skin, press the button, and the injection happens automatically. There is no syringe to fill, no dial to set to a specific milligram number, and no needle to dispose of separately. The pen locks after use. According to NHS guidance on semaglutide, the device is designed specifically to make self-injection straightforward for people without medical training.

One practical detail that catches people out: each pen contains four doses, one for each week of the month. It is not a monthly device you empty in one go. You keep the pen in the fridge between weekly injections, capping it properly after each use. On the question of whether you can adjust the dose yourself, the short answer is no, Wegovy pens are fixed to a single dose per device, and your prescriber decides when and whether to move you to the next strength.

The dose schedule: why the starting strength is lower than you might expect

Wegovy's licensed schedule runs from 0.25 mg up to 2.4 mg, with each strength held for approximately four weeks before the prescriber considers moving up. The first two strengths, 0.25 mg and 0.5 mg, exist mainly so that your digestive system has time to adapt. Nausea and gastrointestinal discomfort are among the most commonly reported side effects, and a slow escalation substantially reduces how pronounced they are. The 0.25 mg pen is not doing very little, it is doing exactly what it is supposed to.

Since April 2026, a 7.2 mg single-dose pen has also been MHRA-approved for adults with obesity (BMI 30 or above), following trial data showing around 20.7% average weight loss over 72 weeks at that dose. This higher-dose option is separate from the standard five-rung schedule; it is not something you arrive at automatically. Your prescriber decides whether it is appropriate. If you are curious about what each pen format looks like and how they differ, the Wegovy pen overview covers the device formats in more detail.

The MHRA-approved titration schedule is described in full in the medication's Patient Information Leaflet, which comes with every prescription. Dosing decisions, including timing of any increase, are always between you and your prescriber, not something to adjust independently based on how you feel.

Injection sites, technique, and a few things worth knowing before your first dose

The three licensed injection sites are the abdomen (avoiding the area immediately around the navel), the front of the thigh, and the outer upper arm. Rotating between sites each week reduces the chance of localised skin reactions. Clean the area with an alcohol swab first; sterile alcohol swabs are available separately if your supply runs low.

Pinch up a fold of skin if you are injecting into the abdomen or thigh, press the pen firmly flat against the skin, then press and hold the injection button until you hear or feel the click and the window confirms the dose has been delivered. Hold the pen in place for a few seconds before removing it. Some people notice a small amount of clear fluid at the site, which is normal.

On timing: most people pick a consistent day each week (same day, roughly same time) because it is easier to remember. The day itself does not need to be clinically significant. If you are thinking about cost context alongside how treatment is structured, where to buy Wegovy and what legitimate supply looks like is worth reading before placing any order.

Used pens contain a needle regardless of the auto-injector design. They should go into a sharps container rather than a household bin; most local councils or GP practices will advise on disposal routes in your area.

Side effects and when to get medical help

The most common side effects reported with the Wegovy injectable pen are gastrointestinal: nausea, vomiting, diarrhoea, constipation, and reflux. These are most noticeable when starting treatment or after a dose increase, and for most people they ease within a week or two. Staying hydrated and keeping meals smaller helps. Fatigue and headache are also reported, particularly in the early weeks.

Rarer but more serious effects need prompt attention. Severe, persistent stomach pain that radiates through to the back (with or without vomiting) can be a sign of pancreatitis; seek urgent medical help if this happens. Gallbladder problems, significant dehydration from persistent vomiting or diarrhoea, and signs of an allergic reaction (swelling, difficulty breathing, rash) are all reasons to contact a healthcare professional without delay. You can report any suspected side effect through the MHRA's Yellow Card scheme, which also accepts reports about suspect medicine sellers.

Wegovy is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. It is not licensed for people under 18. Women using oral contraceptives alongside Wegovy should be aware that any medicine affecting gastric emptying could theoretically affect pill absorption during episodes of vomiting, raise this with your prescriber if it applies to you.

For a broader look at how injectable GLP-1 medicines fit into weight management, including options such as the refillable injection pen for semaglutide, our weight-loss treatment overview sets out the options clearly. If you have questions specific to your situation, our clinical team is straightforward to reach through our contact page. When you are ready to talk to a prescriber about whether Wegovy is right for you, start your free consultation with our prescribers, your answers are reviewed by a real clinician the same day, and treatment is dispatched the day it is approved.